Questions
CJC-1295 Ipamorelin: questions answered from the literature
Direct, cited answers to the questions people most often ask about the pairing.
What does CJC-1295 and Ipamorelin do?
Together they make the pituitary release more growth hormone (GH) than either does alone. A single subcutaneous dose of CJC-1295 (DAC) raised mean plasma GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days in healthy adults; after multiple doses, IGF-1 stayed above baseline up to 28 days [1]. Ipamorelin adds a clean, selective GH pulse [2].
How does CJC-1295 / Ipamorelin work?
Through two separate receptors on the same cell. CJC-1295 binds the GHRH receptor (raising cAMP); ipamorelin binds the ghrelin receptor, GHS-R1a (raising calcium). Because the pathways are independent, co-activation is supra-additive — submaximal GHRP plus GHRH stimulated GH release synergistically in normal men [3], and co-activating both receptors roughly doubled the cAMP signal in cell models [4].
Is CJC-1295 the same as Ipamorelin?
No. They are two different peptides on two different receptors. CJC-1295 is a long-acting GHRH analogue acting at the GHRH receptor; ipamorelin is a selective GHRP acting at the ghrelin receptor (GHS-R1a) [2]. They are combined precisely because they are different and complementary — opening both pathways yields a larger GH pulse than either alone [3].
What is the difference between CJC-1295 with DAC and no DAC?
A chemical handle called the Drug Affinity Complex. With DAC, CJC-1295 covalently binds albumin and lasts about 6 to 8 days, raising GH and IGF-1 for days after one dose [5][1]. No-DAC — Mod GRF (1-29) — lacks that handle and lasts roughly 30 minutes because DPP-IV cleaves it quickly [8]. Same GHRH signal, very different duration.
What is CJC-1295 / Ipamorelin good for?
In the literature, the pairing raises GH and IGF-1 [1] via documented GHRH-plus-GHRP synergy [3]. People in research-use communities most often report deeper sleep, faster recovery, and increased appetite. Those downstream human outcomes are anecdotal for the blend, not demonstrated in any controlled trial — the measured effect is the GH/IGF-1 elevation, not the felt benefits.
What are the bad side effects of CJC-1295 and Ipamorelin?
The class's chief metabolic concern is increased blood glucose from decreased insulin sensitivity [6]. GH excess is also classically tied to water retention, carpal-tunnel-type symptoms, and joint pain. Notably, ipamorelin itself is selective — it did not raise cortisol or ACTH even at more than 200 times its GH ED50 [2], unlike older GHRPs. Community reports add injection-site reactions and transient flushing.
How long do CJC-1295 and Ipamorelin take to work?
Biochemically, fast. A single CJC-1295 (DAC) dose raised GH 2- to 10-fold within days and IGF-1 1.5- to 3-fold for 9 to 11 days [1]; ipamorelin's GH peak is near 40 minutes post-dose [2]. Subjectively, community reports of sleep changes appear within one to two weeks, with body-composition reports described as gradual over a month or more — anecdotal, not clinical.
How many mg of CJC-1295 and Ipamorelin should I take?
This site does not provide human dosing, and no regulatory body has established one — there is no validated human dose for ipamorelin and no human study of the fixed blend. The literature reports studied doses only by species and route: for example, CJC-1295 (DAC) at 30 to 90 µg/kg subcutaneously in healthy adults [1]. Those are research facts, not a regimen for anyone.
Does CJC-1295 raise testosterone?
CJC-1295 itself acts on the GH/IGF-1 axis, not directly on testosterone, and its human data concern GH and IGF-1 [1]. There is a cross-species hint on the ghrelin-receptor side: ipamorelin acetate elevated LH and 11-ketotestosterone in fish [14]. That is a fish study, not human evidence, and no human trial shows CJC-1295 or the blend raising testosterone.
Does Ipamorelin reduce belly fat?
No human ipamorelin trial shows this. The closest evidence is read-across from a related GHRH analogue: a 2026 meta-analysis of tesamorelin found significant visceral-fat reduction (−27.71 cm²) and hepatic-fat reduction (−4.28%) [7]. That suggests GHRH-arm stimulation can reduce visceral fat — but it is tesamorelin data, not ipamorelin or blend data. Ipamorelin also showed a GH-independent adipogenic effect in some mouse work, complicating a simple fat-loss story.
What are the downsides to CJC-1295 / Ipamorelin?
Beyond glucose elevation [6] and GH-excess effects like fluid retention and carpal-tunnel symptoms, the biggest downside is uncertainty: the fixed blend has never been tested in a controlled trial, ipamorelin has no published human pharmacokinetics, and research-grade product has unverified purity. Ipamorelin's own profile is relatively clean — no cortisol or ACTH rise even at high multiples of its GH ED50 [2] — but the blend's long-term safety is simply unknown.
Which is better, Sermorelin or Ipamorelin?
Neither is "better" — they act on different receptors. Sermorelin is a GHRH analogue (GHRH receptor); ipamorelin is a GHRP (ghrelin receptor) [2]. They are complementary, not competitors, which is why a GHRH analogue is often discussed alongside a GHRP. No controlled head-to-head human trial compares them, so any ranking is mechanistic inference, not measured fact.
Can you take both Sermorelin and Ipamorelin together?
The mechanistic rationale for combining a GHRH analogue with a GHRP is well established: in normal men, submaximal GHRP doses combined with GHRH stimulated GH release synergistically, the two acting through independent mechanisms [3]. That said, this site gives no protocols — the synergy is documented for related peptides in research settings, not validated as a fixed human regimen, and no controlled trial tests a sermorelin-plus-ipamorelin combination.
Is Tesamorelin better than Ipamorelin?
Tesamorelin has far stronger human outcome data: a 2026 meta-analysis of 5 RCTs found significant visceral-fat (−27.71 cm²) and hepatic-fat (−4.28%) reductions and increased lean mass (+1.42 kg) with no serious adverse events [7]. Ipamorelin's efficacy data are largely rodent-based with no published human pharmacokinetics [2]. They also act on different receptors, so "better" depends entirely on the goal — but on evidence quality, tesamorelin leads.
Is Ipamorelin stronger than Sermorelin?
There is no controlled head-to-head human trial, so "stronger" is not directly measured. Mechanistically they differ: ipamorelin is a selective ghrelin-receptor agonist that releases GH without raising cortisol or ACTH even at more than 200 times its GH ED50 [2], while sermorelin is a short-acting GHRH analogue. Their value is in combination across the two pathways, not in a head-to-head potency ranking.
Which is safer, Sermorelin or Ipamorelin?
Both belong to the GH-secretagogue class, which is generally well tolerated short-term, with increased blood glucose from reduced insulin sensitivity the chief concern [6]. Ipamorelin's defining safety feature is selectivity — no cortisol or ACTH elevation even at very high multiples of its GH ED50 [2]. Neither has long-term human safety data, and neither is FDA-approved, so neither can be called definitively safer.
What is CJC-1295 / Ipamorelin?
It is a research combination of two peptides: CJC-1295, a long-acting GHRH analogue, and ipamorelin, a selective growth-hormone-releasing peptide acting on the ghrelin receptor [2]. Used together, they aim to amplify GH release through two independent pathways [3]. Neither is FDA-approved, and the fixed blend has never been studied in a controlled human trial.
How much CJC-1295 / Ipamorelin should I take?
No human dose is provided here or established by any regulator. The published record reports studied doses only by species and route — for instance, CJC-1295 (DAC) at 30 to 90 µg/kg subcutaneously in Phase 1 work with healthy adults [1], and ipamorelin doses drawn from rodent studies. These describe experiments, not a regimen, and ipamorelin has no validated human pharmacokinetic dose.
Is CJC-1295 / Ipamorelin safe?
The GH-secretagogue class is generally well tolerated in the short term, but the chief concern is increased blood glucose from decreased insulin sensitivity, and long-term cancer-incidence and mortality data are still needed [6]. The fixed blend itself has no controlled safety data, and ipamorelin — though selective and clean on cortisol/ACTH [2] — has no published human pharmacokinetics. "Safe" cannot be established for an untested combination.
Does CJC-1295 / Ipamorelin work?
It demonstrably raises GH and IGF-1: a single CJC-1295 (DAC) dose raised GH 2- to 10-fold for six or more days and IGF-1 for 9 to 11 days [1], and GHRH-plus-GHRP combinations release GH synergistically [3]. Whether that translates into the muscle, fat, or recovery outcomes people seek has not been measured for the blend in a controlled trial — the biochemistry works; the human endpoints are unproven.
Is Ipamorelin FDA approved?
No. Neither ipamorelin nor CJC-1295 is FDA-approved for any human indication; both are sold only as research chemicals. A review of GH secretagogues found the class generally well tolerated, with increased blood glucose the chief concern and long-term cancer and mortality data still needed [6]. Both are also prohibited at all times in sport under the World Anti-Doping Code (Section S2).
How to reconstitute CJC-1295 / Ipamorelin (5mg)?
This site does not give reconstitution instructions for human use. As laboratory context only: lyophilised peptide is reconstituted with bacteriostatic water (sterile water with 0.9% benzyl alcohol), kept refrigerated at 2–8 °C, and protected from agitation and freeze-thaw, since aqueous solutions degrade over weeks via deamidation [8]. This describes laboratory handling of a research chemical, not a protocol for administration to a person.